Clinical Trials in Seattle

Showing 4941-4960 of 9,312 trials

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

NCT04429191

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

MYELODYSPLASTIC SYNDROME; MDSACUTE MYELOID LEUKEMIA; AML

Jasper Therapeutics, Inc.40 participantsStarted Jul 2020

Duarte, California, United States • Stanford, California, United States • Chicago, Illinois, United States +3 more locations

COMPLETEDPhase 2/3< 1 mile

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

NCT01529268

CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.

Nonalcoholic Fatty Liver Disease (NAFLD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)169 participantsStarted Jun 2012

San Diego, California, United States • San Francisco, California, United States • Atlanta, Georgia, United States +7 more locations

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Find Trials by Condition in Seattle

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Developing a Model to Better Predict Diabetes and/or Risk of Developing Diabetes

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients